ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Organigram Holdings Inc

Organigram Holdings Inc (OGI)

1.71
0.01
(0.88%)
Closed July 15 4:00PM
1.71
0.00
( 0.00% )
Pre Market: 4:00AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.71
Bid
1.65
Ask
1.85
Volume
-
0.00 Day's Range 0.00
0.9702 52 Week Range 2.91
Market Cap
Previous Close
1.71
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
975,814
Shares Outstanding
103,369,558
Dividend Yield
-
PE Ratio
-0.97
Earnings Per Share (EPS)
-2.41
Revenue
161.64M
Net Profit
-248.6M

About Organigram Holdings Inc

Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships. Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

Sector
Pharmaceutical Preparations
Industry
Miscellaneous Metal Ores,nec
Headquarters
Moncton, New Brunswick, Can
Founded
2014
Organigram Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OGI. The last closing price for Organigram was $1.71. Over the last year, Organigram shares have traded in a share price range of $ 0.9702 to $ 2.91.

Organigram currently has 103,369,558 shares outstanding. The market capitalization of Organigram is $176.76 million. Organigram has a price to earnings ratio (PE ratio) of -0.97.

OGI Latest News

Organigram investe in Sanity Group, società leader tedesca nel settore della cannabis

Il secondo investimento "Jupiter" rafforza l'accesso in Europa di Organigram, compreso al mercato in forte crescita della Germania Punti in evidenza: Contestualmente all'investimento, Organigram...

Organigram investiert in Sanity Group, ein führendes deutsches Cannabisunternehmen

Zweite "Jupiter"-Investition stärkt Organigrams Zugang zu Europa, darunter auch zum wachstumsstarken Markt in Deutschland Höhepunkte: Gleichzeitig mit der Investition haben Organigram und die...

Organigram Invests in Sanity Group, a Leading German Cannabis Company

Second “Jupiter” investment strengthens Organigram’s European access, including to the high-growth market of Germany Highlights: Concurrent to the investment, Organigram and Sanity Group have...

Organigram Signs Three Year Supply Agreement with Avida Medical in UK

Over a three-year period, Organigram expects to supply 1,700 kilograms of high-quality medical cannabis flower to Avida Medical, with 500 kilograms expected to be delivered in the first year of...

US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report

U.S. index futures are almost unchanged in pre-market trading this Tuesday, reflecting Wall Street’s caution ahead of key inflation reports. At 6:37 AM, the Dow Jones (DOWI:DJI) futures...

Organigram Reports Second Quarter Fiscal 2024 Results

21% growth in recreational net revenue year-over-year First Jupiter private placement tranche closed adding $41.5 million of cash bringing Organigram's closing cash balance at quarter-end to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.148.917197452231.571.731.554612191.6683889CS
40.21141.51.731.484761541.57550588CS
12-0.19-101.92.171.489758141.82331615CS
26-0.02-1.156069364161.732.911.4812299381.99307316CS
520.159.615384615381.562.910.970210788381.73594163CS
156-8.89-83.867924528310.611.680.970226067996.16280268CS
260-22.89-93.048780487824.627.80.970245403329.34983721CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CDTConduit Pharmaceuticals Inc
$ 0.4588
(91.17%)
19.75M
WNWMeiwu Technology Company Ltd
$ 1.245
(39.89%)
2.2M
SYRASyra Health Corporation
$ 1.75
(31.09%)
1
WINTWindtree Therapeutics Inc
$ 4.50
(21.62%)
10
TPCSTechPrecision Corporation
$ 4.36
(17.18%)
1
AMIXAutonomix Medical Inc
$ 1.13
(-18.12%)
412.36k
GRNQGreenpro Capital Corporation
$ 0.9665
(-18.09%)
80.61k
AREBAmerican Rebel Holdings Inc
$ 0.5699
(-15.32%)
141.53k
TANHTantech Holdings Ltd
$ 0.5187
(-15.12%)
1.08M
CYNCYNGN Inc
$ 7.82
(-14.81%)
11.58k
CDTConduit Pharmaceuticals Inc
$ 0.4557
(89.88%)
19.71M
KRKR36Kr Holdings Inc
$ 0.3075
(3.47%)
4.37M
SLNASelina Hospitality PLC
$ 0.0663
(5.91%)
2.4M
WNWMeiwu Technology Company Ltd
$ 1.24
(39.33%)
2.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.2201
(-3.04%)
1.43M

OGI Discussion

View Posts
john1311 john1311 1 day ago
This deal with Sanity if good forward thinking... I wonder what is the increase in medical canna customers in Germany since legalisation on April 1...? Does anyone have the figures...?
👍️0
john1311 john1311 1 day ago
Thanks for that, Hunch.
👍️0
Hunchbackgeek Hunchbackgeek 2 weeks ago
Organigram Invests in Leading German Cannabis Company Sanity~Group... https://www.organigram.ca/press-releases/organigram-invests-in-sanity-group-a-leading-german-cannabis-company

Organigram Invests in Sanity Group, a Leading German Cannabis Company June 25th, 2024

Second “Jupiter” investment strengthens Organigram’s European access, including to the high-growth market of Germany.

Highlights:

Concurrent to the investment, Organigram and Sanity Group have entered into a new supply agreement to include significantly higher volumes and the intention to work together on the commercialization of Organigram’s brands and intellectual property (IP) in Germany.
Investment in the form of an unsecured convertible note combined with a minority equity stake in Sanity Group. Organigram entitled to appoint a representative to Sanity Group’s Board of Directors.

TORONTO, June 25, 2024 --- Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its first significant strategic investment aimed at expanding its presence in the European cannabis market. Using proceeds from its Jupiter strategic investment pool, the Company has agreed to invest €14 million (~ C$21 million) initially comprised of €11.5 million via an unsecured convertible note and €2.5 million to purchase equity interests from existing Sanity Group founders and shareholders providing the Company with a minority stake in Berlin-based cannabis company Sanity Group GmbH (“Sanity” or “Sanity Group”). In addition, the Company may advance another €3 million (~ C$4.5 million) as a second tranche of the unsecured convertible note for future opportunities to be pursued by Sanity subject to the satisfaction of certain conditions.

Sanity has quickly established itself as a leader in the German cannabis market where it maintains a robust distribution network with over 2,000 pharmacies working with approximately 5,000 physicians in Germany. Sanity currently holds approximately a 10% share of the German medical cannabis market where its medical brand, avaay, is estimated to hold the number two position and has shown impressive revenue growth since the recent legal reforms regarding partial legalization of adult-use recreational cannabis in Germany. Additionally, Sanity is currently participating in a Swiss recreational cannabis pilot program in the Basel canton, with one store operational and a plan to expand its retail footprint in Switzerland. In the coming months, Sanity is expected to invest in proprietary distribution channels providing it with what it believes will be a competitive advantage that capitalizes on new medical consumers entering the market.

The Company's investment also expands the previously announced supply agreement between Organigram and Sanity Group. Until such time as Organigram receives EU-GMP certification at its Moncton production facility, Sanity Group has committed to purchase significantly higher annual volumes of dried flower under the new agreement as compared to the previous one. Once Organigram receives EU-GMP certification in Moncton, Sanity Group will shift its annual purchase commitment from Organigram to a percentage of its overall assortment of flower offerings for the European market. Organigram expects to complete its final EU-GMP audit before the end of the calendar year. Additionally, the new commercial agreement contemplates, subject to terms and conditions, avenues by which Organigram can launch its industry-leading brands, products, and IP in the German market.

“A meaningful presence in Germany and Europe are essential to achieving our ambitions to be a global cannabis leader. We believe that after Canada, Germany will emerge as one of the more promising markets under a nationally legal model,” said Paolo De Luca, Chief Strategy Officer of Organigram. “With its evolving program for medical cannabis and recent limited legalization for recreational consumption, Germany may eventually adopt a full adult-use cannabis framework. This growth opportunity is magnified by positive regulatory developments in several neighbouring European jurisdictions where Sanity Group is expanding its presence,” he concluded.

“Our investment in Sanity Group establishes a significant European footprint for us. Organigram benefits from Sanity’s expertise and insights in the German (and in the future) other European cannabis markets. This has the potential to provide a pathway for us to launch our own brands and industry-leading IP through Sanity’s extensive distribution network. This relationship also bolsters our European revenue generation through a significantly expanded commercial agreement,” said Beena Goldenberg, CEO of Organigram.

“We are extremely pleased to close this strategic financing with Organigram who has consistently demonstrated itself to be a leader in the highly competitive and regulated Canadian cannabis market,” said Finn Hansel, co-founder and CEO of Sanity Group. “With its commitment to responsible R&D, innovation and product development, including through its relationship with BAT (British American Tobacco), we feel that we have chosen a partner that will support us in becoming a leader in the rapidly expanding legal European markets,” he concluded.



The German and European Cannabis Market

The German cannabis industry is poised for significant expansion following the recreational cannabis legal reforms enacted on April 1, 2024. According to BDSA estimates, Germany is expected to bring in ~USD$1.5 billion in total sales in 2024, set to grow to ~USD$3.7 billion by 2027. This remarkable growth is driven by a 30-50% increase in medical cannabis prescriptions since April 1, 2024, a likely result of the regulatory framework changes that may have accelerated the shift by consumers from the illicit market to the legal market. Germany’s cannabis industry progress is also anticipated to create a ‘ripple effect’, potentially shaping economic, regulatory, public health, and cultural landscapes across Europe. The success of Germany's cannabis industry could serve as a catalyst for a more unified and progressive approach to cannabis legalization and regulation across the continent.



Strategic Rationale and Potential Opportunities

Establishes a significant European footprint for Organigram through a leading regional cannabis company with a presence in multiple markets.
Organigram benefits from Sanity’s expertise and insights in the German (and in future) other European cannabis markets.
Provides a pathway for Organigram to launch its own brands and industry-leading IP in Europe through Sanity’s extensive distribution network.
Bolsters Organigram’s European revenue generation through an expanded commercial agreement with improved terms and commitments.
Further investment opportunities may allow Organigram to increase its unsecured convertible note and ownership position in Sanity Group.


Investment Details

€14 million initial investment consists of €11.5 million structured as an unsecured convertible note (the “Note”) issued by Sanity Group to the Company as lender and €2.5 million of already issued equity interests purchased from existing shareholders.
The Note yields 10% annual paid-in-kind (PIK) interest for a minimum of three years and is convertible at a discount to the price established by Sanity Group’s next qualified financing into the most senior class of shares (currently Series B).
Organigram has an option, subject to certain terms and conditions, to invest an additional €3 million on substantially the same terms as the Note which would bring its total investment to €17 million.
Sanity’s use of proceeds includes investments in various initiatives that are expected to give it access to over 100,000 patients, and aid in recreational cannabis pilot project expansion in applicable regions.
Notable previous investors in Sanity Group include BAT, Casa Verde Capital (Snoop Dog), Will.i.am (Black Eyed Peas), Navy Capital, Scooter Braun and Alyssa Milano amongst others.




About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary Organigram Inc. is a licensed producer of cannabis, cannabis-derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality cannabis for adult recreational consumers, as well as developing international business partnerships to expand the Company’s global footprint. Organigram has also developed and acquired a portfolio of adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates production facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).



About Sanity Group

Berlin-based Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products that utilize cannabinoids. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel, includes Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (minority investment in finished pharmaceuticals), and VAAY (wellbeing). Close to Frankfurt, Sanity Group also operates a storage facility for cannabis extracts and flower. More information can be found on sanitygroup.com/press.



Forward-Looking Information

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram and Sanity Group to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include applicable regulatory and market conditions in Germany and other European markets in future, the ability to conclude terms related to any future licensing and brand opportunities in Germany, the receipt of any required regulatory and shareholder approvals and consents from time to time and factors and risks disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

SOURCE: https://www.organigram.ca/press-releases/organigram-invests-in-sanity-group-a-leading-german-cannabis-company

For Investor Relations enquiries:

Max Schwartz, Director of Investor Relations

investors@organigram.ca



For Media enquiries:
Megan McCrae, Senior Vice President – Global Brands and Corporate Affairs
megan.mccrae@organigram.ca
👍️ 1 💚 1
Bazwar6 Bazwar6 3 weeks ago
https://www.coastreporter.net/the-mix/organigram-takes-stake-in-german-cannabis-firm-sanity-group-with-21m-investment-9133134
👍️ 1 💚 1
WALL STREET KID WALL STREET KID 4 weeks ago
That's awesome thanks HunchbackGeek
👍️ 1 💚 1
Hunchbackgeek Hunchbackgeek 4 weeks ago
OGI OrganiGram Investor Presentation https://www.organigram.ca/investor-presentation
👍️ 1 💚 1
Hunchbackgeek Hunchbackgeek 4 weeks ago
OGI Signs 3-Year Suppy Agreement, Avida UK
Organigram Signs Three Year Supply Agreement with Avida Medical in UK May 28th, 2024
https://www.organigram.ca/organigram-signs-three-year-supply-agreement-with-avida-medical-in-uk

Over a three-year period, Organigram expects to supply 1,700 kilograms of high-quality medical cannabis flower to Avida Medical, with 500 kilograms expected to be delivered in the first year of the agreement.

Avida Medical to become Organigram’s second international medical cannabis customer in the UK.

Organigram to grant Avida Medical strain exclusivity in the UK for three strains.

To date, Organigram has established international supply agreements with a total of seven medical cannabis customers in Australia, Germany, Israel, and the UK, aligned to its strategy to extend its reach beyond Canada into global markets.

Toronto, Ontario, May 28, 2024 – Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and specials medicines manufacturing business.

Subject to the terms of the Agreement, the Company expects to supply 1,700 kilograms of high-quality, indoor-grown dried cannabis flower to Avida Medical in the UK over a period of three years.

"We are pleased to partner with Avida Medical in the UK, marking yet another exciting milestone for Organigram's expansion into the global market. As frontrunners in the cannabis industry, we recognize the immense potential of the UK market. Our decision to further expand into this market stems from our commitment to ensuring patients have access to reliable, high-quality medical cannabis offerings,” said Tim Emberg, Chief Commercial Officer of Organigram. “With our extensive industry expertise in cultivation and production, we are poised to elevate accessibility and cater to the evolving requirements of patients in the UK. We are confident that this strategic move will not only strengthen our international presence but also reinforces our objective of advancing global access to medical cannabis,” Emberg concluded.

“Our agreement with Organigram exemplifies our commitment to providing the highest quality medicine and service to patients. The UK is home to one of the largest patient populations using medicinal cannabis in Europe, and this is set to grow exponentially over the next four years. As the market matures, it is those producers and manufacturers that have focused on ensuring the highest quality of their products and processes, that will determine the companies that succeed,” commented Paul Parkinson, Chief Executive Officer, Avida Medical.

“This is a hugely positive collaboration for Avida Medical and brings us a step closer to becoming one of the pre-eminent manufacturers of medicinal cannabis products here in the UK,” he added.

FULL NEWS RELEASE HERE: https://www.organigram.ca/organigram-signs-three-year-supply-agreement-with-avida-medical-in-uk
👍️ 2 💚 2 💯 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 4 weeks ago
Organigram Reports Second Quarter Fiscal 2024 Results https://www.organigram.ca/organigram-reports-second-quarter-fiscal-2024-results May/15/2024

~ 21% growth in recreational net revenue year-over-year
~ First Jupiter private placement tranche closed adding $41.5 million of cash bringing Organigram's closing cash balance at quarter-end to $83.6 million
~ Subsequent to quarter end, closed $28.8 million oversubscribed marketed offering, which when combined with the remaining two anticipated Jupiter tranches
will increase cash position by additional $110 million
~ Company's recent investment in Steady State LLC (d/b/a Open Book Extracts) ("OBX") adds to
growing U.S. portfolio, which includes Phylos Bioscience Inc. ("Phylos")
~ Organigram's U.S.-based strategic investments may benefit from expected change in rescheduling of
cannabis by the Drug Enforcement Administration from
Schedule I to Schedule III

FULL REPORT HERE:
https://www.organigram.ca/organigram-reports-second-quarter-fiscal-2024-results


.
👍️ 1 💚 1
cashbyers cashbyers 1 month ago
on’t overlook this undervalued synergy!

British American Tobacco already has existing deals with both Charlottes Web Holdings $CWBHF and Organigram Holdings $OGI… There are a few possibilities for how BAT could leverage its partnerships with both companies:

Joint Investment: BAT, Charlottes Web, and Organigram could collaborate on a joint venture or even a merger (depending on regulations) to create a larger cannabis and CBD company. This would require significant planning and navigating potential regulatory hurdles.”

Market Expansion: BATs global reach could be valuable for both Charlottes Web and Organigram. BAT could help them enter new markets where cannabis or CBD products are legal. For example, BAT might leverage its existing distribution channels for these products.

Knowledge Sharing: BAT could act as a bridge between the two companies, facilitating knowledge sharing and best practices in areas like marketing, regulatory compliance, and cultivation techniques.
👍️ 1 💚 1
WALL STREET KID WALL STREET KID 2 months ago
Thanks Bud :)
🇮🇩 1 🇮🇴 1 🇹🇹 1 👍️ 1 💚 1 💩 1 🤡 1
Hunchbackgeek Hunchbackgeek 2 months ago
Orginigram Second Quarter Fiscal 2024 Results May/14/2024

Organigram to Report Second Quarter Fiscal 2024 Results on May 14, 2024
TORONTO—(BUSINESS WIRE)—May 8, 2024—Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2024 ended March 31, 2024, on Tuesday, May 14, 2024, prior to market open.

The Company will host a conference call to discuss its results with details as follows:

Date: Tuesday, May 14, 2024

Time: 8:00 am Eastern Time

To register for the conference call, please use this link:

https://registrations.events/direct/Q4I9676693302

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast:

https://events.q4inc.com/attendee/619527249

Participants will receive their details via email.

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.


About Organigram
Organigram is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc. a licensed producer of cannabis, cannabis- derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks disclosed in the Circular, and the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For Investor Relations enquiries:

Max Schwartz, Director of Investor Relations
investors@organigram.ca

For Media enquiries:

Megan McCrae, Senior Vice President – Marketing and Communications
megan.mccrae@organigram.ca
👍️0
Hunchbackgeek Hunchbackgeek 2 months ago
Organigram to Report Second Quarter Fiscal 2024 Results on May 14, 2024
TORONTO—(BUSINESS WIRE)—May 8, 2024—Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2024 ended March 31, 2024, on Tuesday, May 14, 2024, prior to market open.

The Company will host a conference call to discuss its results with details as follows:

Date: Tuesday, May 14, 2024

Time: 8:00 am Eastern Time

To register for the conference call, please use this link:

https://registrations.events/direct/Q4I9676693302

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast:

https://events.q4inc.com/attendee/619527249

Participants will receive their details via email.

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.


About Organigram
Organigram is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc. a licensed producer of cannabis, cannabis- derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks disclosed in the Circular, and the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For Investor Relations enquiries:

Max Schwartz, Director of Investor Relations
investors@organigram.ca

For Media enquiries:

Megan McCrae, Senior Vice President – Marketing and Communications
megan.mccrae@organigram.ca
👍️0
john1311 john1311 3 months ago
Thanks, Hunch.... this is great news... sounds a winning innovative product... it is just a pity we cannot legally consume high quality milled flower SHRED on this side of the pond... unfortunately Europe, US and much of the world, are so far behind Canada... if the Ottawa government was smart it would reduce the tax burned on LPs to normal, and not unfair draconian as at present, and allow these Canadian legal operators to retain capital and so grow themselves into mammoth international companies, which would be to the ultimate benefit of the Ottawa government, and the Canadian taxpayer.... cheers...
👍️ 1 😎 1
Hunchbackgeek Hunchbackgeek 3 months ago
Organigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales APRIL 3RD, 2024
https://www.organigram.ca/press-releases/organigrams-popular-shred-brand-surpasses-200-million-in-yearly-retail-sales

😎 Always good to hear from you John.
💩 1 🤡 1
john1311 john1311 3 months ago
Thanks for that, Hunch... now I understand market movement from that... OGI share price ought to be way better than it is today.... but then again, so should peace on earth...
👍️ 2 💚 2 💱 1 💲 1 🚀 1
WALL STREET KID WALL STREET KID 4 months ago
Thanks HBG
🇮🇩 1 🇮🇴 1 🇹🇹 1 👍️ 1 💚 1 💩 1 🤡 1
Hunchbackgeek Hunchbackgeek 4 months ago
OGI~Organigram Announces Pricing of Overnight Marketed Public Offering ~ March 27th, 2024
https://www.organigram.ca/press-releases/organigram-announces-pricing-of-overnight-marketed-public-offering
👍️ 2 💚 2 💱 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 4 months ago
OGI~Organigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter Investment ~ MARCH 26TH, 2024
https://www.organigram.ca/press-releases/organigram-invests-in-us-based-open-book-extracts-representing-inaugural-jupiter
👍️ 2 💚 2 💱 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 4 months ago
OGI~Organigram Receives Health Canada’s Final Redetermination on Jolts ~ March 25th, 2024
https://www.organigram.ca/press-releases/organigram-receives-health-canadas-final-redetermination-on-jolts
👍️ 2 💚 2 💱 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 4 months ago
OGI~Organigram Applauds the Standing Committee on Finance’s Recommendation on Excise Duty ~ February 28th, 2024OGI~
https://www.organigram.ca/press-releases/organigram-applauds-the-standing-committee-on-finances-recommendation-on-excise-1
👍️ 2 💚 2 💱 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 5 months ago
Organigram Applauds the Standing Committee on Finance’s Recommendation on Excise Duty
February 28th, 2024

https://www.organigram.ca/press-releases/organigram-applauds-the-standing-committee-on-finances-recommendation-on-excise-1


Revised Excise Framework Remains One of the Most Critical Reforms Required to Ensure the Long-Term Viability of the Cannabis Industry

Toronto, Ontario – February 28, 2024 - Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”) enthusiastically supports the Standing Committee on Finance’s recent recommendation on the Excise Duty framework.

In a recently released report, titled ‘Shaping our Economic Future: Canadian Priorities,’ the House of Commons Standing Committee on Finance has unanimously recommended adjusting the excise duty formula for cannabis so that it is limited to a 10% ad valorem rate, and modifying the duty's operation, including applying excise stamps on cannabis products.

Based on a survey conducted by the Cannabis Council of Canada, licensed producers currently pay up to 35% of top-line revenue in excise duties because of an erroneous assumption at the time of legalization that the price of cannabis flower would be approximately $10 per gram to the retail consumer. In reality, the price per gram of cannabis flower has fallen to as low as approximately $3 per gram, limiting cannabis companies’ ability to remain competitive on pricing, invest in innovation, retain jobs, and ultimately support the government’s stated objectives of illicit market conversion and promoting public health and safety.

“The pre-budget recommendation could not have come at a better time.” said Beena Goldenberg, CEO of Organigram. “Excise reform is critical to the long-term viability of the Canadian cannabis industry. The positive impact of the proposed reduction to a 10% ad valorem rate on the sustainability of the sector cannot be underestimated. We sincerely hope that the recommendation made by the Finance Committee is adopted by the Federal, Provincial and Territorial governments so that Canada can retain its position as global leader in the emerging cannabis movement.”

“We are also encouraged by recent reports indicating that the CRA is taking proactive measures to level the playing field by collecting more diligently from LPs who have fallen behind on their remittances for excise duties”, added Beena.

About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc. a licensed producer of cannabis, cannabis-derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include adoption of budget recommendations and timing thereof, changes to market conditions, consumer preferences and regulatory climate and factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.


For Media enquiries:

Megan McCrae
Senior Vice President, Global Brands and Corporate Affairs
megan.mccrae@organigram.ca
Organigram
👋 2 👍️ 2 💚 2 💯 2 🤑 2
Hunchbackgeek Hunchbackgeek 5 months ago
It's reall it's on their Website. I'll post it as well. Thank you Bazwar6. 😉
👍️ 2 💚 2 💯 2 😎 2 🤑 2
Bazwar6 Bazwar6 5 months ago
If this happens this is great news for Canadian LPs

https://www.businesswire.com/news/home/20240228644763/en/Organigram-Applauds-the-Standing-Committee-on-Finance’s-Recommendation-on-Excise-Duty
👍️ 2 💚 1 🤑 1
WALL STREET KID WALL STREET KID 5 months ago
That's awesome thanks bud
🇮🇩 1 🇮🇴 1 🇹🇹 1 👍️ 1 💚 1 💩 1 💯 1 😎 1 🤑 1 🤡 1
Hunchbackgeek Hunchbackgeek 5 months ago
OGI~Organigram Reports First Quarter Fiscal 2024 Results https://www.organigram.ca/press-releases/organigram-reports-first-quarter-fiscal-2024-results

Achieved positive cash flow from operations, solidified #2 market position in Canada among licensed producers, significantly improved margins sequentially quarter-over-quarter, and closed first $41.5 million tranche of previously announced $124.6 million investment from BAT
👍️ 2 💚 1 💯 1 💹 1 🚀 2
WALL STREET KID WALL STREET KID 5 months ago
Thanks for the update Hunchbackgeek
👍️ 1 💚 1
Bazwar6 Bazwar6 5 months ago
https://www.marketwatch.com/story/organigram-shares-fall-on-loss-revenue-miss-as-international-sales-lag-in-1q-b9d4779a
👍️0
Hunchbackgeek Hunchbackgeek 5 months ago
OGI~Organigram to Report First Quarter Fiscal 2024 Results on February 13, 2024
February 7th, 2024

https://investors.organigram.ca/press-releases/organigram-to-report-first-quarter-fiscal-2024-results-on-february-13-2024
👍️ 2 💚 1
Hunchbackgeek Hunchbackgeek 5 months ago
OGI~Organigram Completes First Shipment to Germany, Extending its International Reach

January 31st, 2024

https://investors.organigram.ca/press-releases/organigram-completes-first-shipment-to-germany-extending-its-international-reach
👍️ 2 💚 1
Hunchbackgeek Hunchbackgeek 5 months ago
OGI Happy New Year to you! Super to hear from you John! OGI Always surprises me. It's a good company. We'll see, yes, I still have my shares too, so does our friend. 😎
👍️ 2 💚 1
Bazwar6 Bazwar6 5 months ago
https://www.investorsobserver.com/news/stock-update/organigram-holdings-inc-ogi-stock-adds-26-99-this-week-should-you-buy
👍️ 2 💚 1
john1311 john1311 5 months ago
Happy new year Hunch.... isn't it time this sector awakens again...? I've still a few thousand shares in OGI... I did so well with OGI that I had to hold some shares through the bad times because of my fondness for this company... now, isn't it time OGI enjoys its bright future...
👍️ 2 😎 1
Bazwar6 Bazwar6 5 months ago
Brings back good memories
👍️ 1
mte1955 mte1955 5 months ago
Haven't seen this in a while...YAY!
👍️ 1
Hunchbackgeek Hunchbackgeek 5 months ago
OGI Excellent! Thank you WeedIsGreen!
👍️ 2 💚 1
Hunchbackgeek Hunchbackgeek 5 months ago
OGI OrganiGram Wonderful to hear from you ZZ. ♥️
👍️ 2 💚 1
weedisgreen weedisgreen 5 months ago
Didn't see this good info brought out for discussion!

https://www.businesswire.com/news/home/20240131211876/en/
👍️ 2
zig zag zig zag 5 months ago
Hi Geek
👍️ 2
Bazwar6 Bazwar6 6 months ago
The news says they are buying the shares at $3.2203. The current price is $2.20 Canadian

So why isn't the share price $3.22 Canadian currently, shouldn't it be?
👍️0
morokoy morokoy 6 months ago
3.2200 CAD = 2.3925 USD
👍️0
Bazwar6 Bazwar6 6 months ago
Can someone please explain

, the Investor acquired 12,893,175 common shares of the Company at a price of C$3.2203 per share (the “Per Share Price

Based on the above paragraph why is the share price of organic gram not now $3.22?
👍️0
Hunchbackgeek Hunchbackgeek 6 months ago

Organigram Announces the First Tranche Closing from BAT Investment January 24th, 2024

TORONTO, Ontario – January 24, 2024 – Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that it has closed the first of three tranches of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the first tranche closing, the Investor acquired 12,893,175 common shares of the Company at a price of C$3.2203 per share (the “Per Share Price”) for gross proceeds of C$41,519,891. The remaining 25,786,350 shares subscribed for shall be issued at the Per Share Price in two further equal tranches on or around August 30, 2024 and February 28, 2025.

“With this transformational deal now formally approved by shareholders and with the first tranche funded, we look forward to delivering on our objectives of geographic and technological growth as well as product expansion,” said Paolo De Luca, Chief Strategy Officer of Organigram. “Since we announced this transaction on November 6, 2023 we have seen tremendous interest from cannabis companies looking for strategic partnership opportunities and growth capital. Organigram, with its strong balance sheet and dedicated Jupiter capital pool, is uniquely positioned to take advantage of a growing set of emerging opportunities”.

“Jupiter” Strategic Investment Pool Will Accelerate Organigram’s Growth Ambitions
The majority of the C$124.6 million Investment will be used by Organigram to create a strategic investment pool, named Jupiter. Jupiter will target investments in emerging cannabis opportunities that will enable Organigram to apply its industry-leading capabilities to new markets. Management has identified that geographic expansion is a strategic priority and this opportunity presents the Company with the capital to lay global foundations as the legal recreational cannabis market continues to see significant growth. Organigram maintains the highest level of regulatory and product stewardship and will continue to monitor the cannabis regulatory environment carefully. As a result, all potential investments will undertake rigorous legal compliance and due diligence processes.

Organigram has 10 years of experience within the Canadian cannabis market and has already made several successful cannabis investments. The acquisition and integration of the Edibles and Infusions Corporation, Laurentian Organics Inc., and more recently, its investment in Phylos Bioscience Inc. has propelled Organigram to a market leadership position in gummies and hash, as well as enabling the Company to be first to launch THCV products in Canada. This proven track record combined with Organigram’s industry knowledge can now be applied at a larger scale through Jupiter.

Amended and Restated Investor Rights Agreement
In connection with the first tranche closing, the Company and the Investor entered into an amended and restated investor rights agreement (the “Amended & Restated IRA”), which amended and restated the current investor rights agreement dated March 10, 2021 between the Company and the Investor. The Amended & Restated IRA, among other things, grants the Investor certain customary registration rights, pre-emptive rights, top-up rights, information rights, consent rights and nomination rights. A copy of the Amended & Restated IRA will be available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

Further details relating to the Investment can be found in the press release issued by the Company on November 6, 2023 and the Company’s management information circular dated December 20, 2023 (the “Circular”).

About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc. a licensed producer of cannabis, cannabis-derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks disclosed in the Circular, and the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For Investor Relations enquiries:

Max Schwartz, Director of Investor Relations
investors@organigram.ca

For Media enquiries:

Megan McCrae, Senior Vice President – Marketing and Communications
megan.mccrae@organigram.ca

SOURCE: https://www.organigram.ca/press-releases/organigram-announces-the-first-tranche-closing-from-bat-investment



.
👋 2 👍️ 2 💚 2 😎 2 🤑 2
Hunchbackgeek Hunchbackgeek 6 months ago
OGI Thanks Gollums.
👍️ 2 💚 2 💯 2 😎 2 🤑 2
VH Gambler VH Gambler 6 months ago
Very negative lead for "scanners" but, then, there is the rest of the story.
the rest of the story tells about investors that are initiating or increasing their holdings.
👍️ 1
WALL STREET KID WALL STREET KID 6 months ago
Mirae Asset Global Investments Co. Ltd. owned approximately 1.39% of Organigram worth $1,487,000 as of its most recent SEC filing
🇮🇩 1 🇮🇴 1 🇹🇹 1 👍️ 1 💚 1 💩 1 💯 1 😎 1 🤡 1 ♥️ 1
Bazwar6 Bazwar6 6 months ago
https://www.marketbeat.com/instant-alerts/nasdaq-ogi-sec-filing-2024-01-23/
👍️0
VH Gambler VH Gambler 6 months ago
New Director, continuing the BAT influence:
https://financialpost.com/pmn/business-wire-news-releases-pmn/organigram-announces-appointment-of-karina-gehring-to-board-of-directors
👍️ 1 💚 1 💲 1 ❤️ 1
weedisgreen weedisgreen 6 months ago
Yeah, nice jump up. Whole sector is getting hot!
👍️ 1 💚 1 💲 1 ❤️ 1
VH Gambler VH Gambler 6 months ago
Who said there was no life left in OGI?
👍️ 1 💚 1 💲 1 ❤️ 1
WALL STREET KID WALL STREET KID 6 months ago
Thanks Hunchbackgeek
👍️ 1 👎🏻 1 💚 1 💩 1 😊 1 😎 1 🤡 1

Your Recent History

Delayed Upgrade Clock